The prevalence of overweight and obesity among Croatian hospitalized coronary heart disease patients [Prevalencija prekomjerne tjelesne težine i pretilosti u hospitaliziranih koronarnih bolesnika u Hrvatskoj] by Vražić, Hrvoje et al.
Coll. Antropol. 36 (2012) Suppl. 1: 211–216
Original scientific paper
The Prevalence of Overweight and Obesity among
Croatian Hospitalized Coronary Heart Disease
Patients
Hrvoje Vra`i}1, Jozica [iki}1,2, Tomo Lucijani}1,3, Boris Star~evi}1, Pejo Samard`i}4,
Dubravko Tr{inski5, Kre{imir [utalo6, Jure Mirat2, Luka Zaputovi}7 and Mijo Bergovec1,3
1 University of Zagreb, Dubrava University Hospital, Department of Internal Medicine, Division of Cardiology, Zagreb, Croatia
2 University of Zagreb, »Sveti Duh« University Hospital, Department of Internal Medicine, Division of Cardiology, Zagreb, Croatia
3 University of Zagreb, School of Medicine, Zagreb, Croatia
4 »Dr. Josip Ben~evi}« Slavonski Brod General Hospital, Department of Internal Medicine, Division of Cardiology, Slavonski Brod,
Croatia
5 Vara`din General Hospital, Department of Internal Medicine, Division of Cardiology, Vara`din, Croatia
6 »Dr. Tomislav Bardek« Koprivnica General Hospital, Department of Internal Medicine, Division of Cardiology, Koprivnica, Croatia
7 University of Rijeka, Rijeka University Hospital Centre, Department of Internal Medicine, Division of Cardiology, Rijeka, Croatia
A B S T R A C T
The aim of this article was to investigate the prevalence of overweight and obesity using selected anthropometric vari-
ables in a sample of hospitalized coronary heart disease (CHD) patients in Croatia (N=1,298). Prevalence of overweight
and obesity in surveyed patient population was high: 48.2% of participants were overweight and 28.6% were obese ac-
cording to their body mass index; measured through waist-to-hip ratio 54.5% of participants were centrally obese. These
data on prevalences of overweight, obesity and central obesity show that although there are some reassuring trends, there
is still considerable amount of work to be done if the prevalence of this cardiovascular risk factor is to be reduced further
among Croatian CHD patients. While the prevalence of obesity seems to be on the decline, the prevalence of overweight is
rising, which may be just an early warning sign of an incoming wave of obesity epidemic in future years.
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Introduction
Overweight and obesity are connected with develop-
ment of cardiovascular disease (CVD)1,2 and mortality
from CVD3. Besides these effects, the presence of obesity
includes various health problems (such as sleep disor-
ders, dyspnoea during mild exertion, sweating, social
stigmatization and discrimination, etc.) which all reduce
the quality of life, increasing the risk of depression4,5 and
shortening one’s expected life expectancy for 5–20 ye-
ars6. A special subcategory is central obesity (as mea-
sured through waist-to-hip ratio – WHR), since it has ad-
ditional negative effects on one’s health – it increases the
risk for cardiometabolic diseases7, incidence of cardiovas-
cular events8 and mortality from cardiovascular and ma-
lignant diseases9. The results of the famous Framingham
Offspring study, in which the body mass index (BMI) was
used to determine presence of obesity, have shown that
presence of obesity is significant for prediction of occur-
rence of coronary heart disease (CHD) and cerebrovas-
cular disease10.
The World Health Organization (WHO) recommends
that men have a waist circumference of up to 102 cm, and
women of up to 88 cm11, while WHR of >1 for men, and
>0.85 for women is considered indicative for obesity12.
European Society of Cardiology (ESC) Guidelines from
2007 recommend to keep the BMI <25 kg/m2 and avoid-
ance of central obesity as a measure in primary preven-
tion (it is advised that men with waist circumference
94–102 cm and women with waist circumference 80–88
cm do not increase their weight, while men with waist
circumference bigger than 102 cm and women with waist
circumference bigger than 88 cm are strongly advised to
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reduce their body weight)13,14; in the field of secondary
prevention it is recommended in patients which have had
a myocardial infarction with ST-segment elevation to re-
duce their body weight when their BMI is 30 kg/m2 and
when their waist circumference is >102/88 cm (men/
women)15. While all the used measures of overweight and
obesity can be confusing, both for the health professional
and for the patient, it is reassuring that the 2007 ESC
Guidelines explicitly state that there is no single best
measure of overweight/obesity and central obesity, and it
is possible to use BMI, WHR or just waist circumference
when estimating the risk13,14. Croatian Adult Health
Survey (CAHS) data from 2003 showed that 38.11% of
the surveyed population was overweight (BMI 25 kg/m2),
20.34% was obese (BMI 30 kg/m2) and that 43.52% had
increased waist circumference. In men the prevalences
were 43.2%, 20.1% and 34.98% respectively, while in
women they were 33.6%, 20.6% and 51.13%. The authors
concluded that as much as 60% of adult population in
Croatia was overweight, and as much as 40% was cen-
trally obese16,17.
Materials and Methods
The survey included 1,298 patients hospitalized be-
tween October 1st 2007 and January 7th 2010 for acute or
chronic CHD in various hospitals in Croatia. It was per-
formed in the above mentioned period in Dubrava Uni-
versity Hospital (Zagreb), Sveti Duh University Hospital
(Zagreb), Bjelovar General Hospital, ^akovec General
Hospital, Karlovac General Hospital, Koprivnica General
Hospital, Slavonski Brod General Hospital, Vara`din
General Hospital, Rijeka University Hospital Centre,
Pula General Hospital, Split University Hospital Centre,
Dubrovnik General Hospital and Zadar General Hospital.
A special questionnaire was produced for this study
which allowed recording of required data. Questionnaire
was made after series of consultations with experts and
literature and it was compiled by model of large clinical
trials conducted in Europe and Croatia [INTERHEART18,
EUROASPIRE (European action on secondary preven-
tion by intervention to reduce events) I19 and II20, EH-
-UH (Epidemiology of hypertension in Croatia)21, TAS-
PIC-CRO (Treatment and secondary prevention of is-
chemic coronary events in Croatia)22]. This allowed the
investigators to be able to efficiently compare results.
Most of the questions had multiple answers offered in ad-
vance to acquire greater accuracy. Data was collected on
patient history (personal and family history), age, sex
and information on cardiovascular risk factors and dis-
charge diagnoses. Physical examination was performed,
results of which were recorded – weight, height, waist
circumference and hip circumference. Weight and height
were measured while the patient was in light clothes
without shoes. The scales that were used were cali-
brated. This data was used to calculate the body mass in-
dex (BMI, weight in kg divided with square of height in
meters, unit is kg/m2). Overweight was defined as BMI
25, and <30 kg/m2; obesity was defined as BMI 30
kg/m2; as described in the 2007 ESC Guidelines for the
prevention of CVD13,14. Patient’s waist and hip circum-
ferences were also measured in order to perform the cal-
culation of waist to hip ratio (WHR, waist circumference
in centimetres divided by hip circumference in centi-
metres). WHR values indicative of central obesity were
those >0.85 in women and >1 in men12.
Data were collected by physicians or trained person-
nel (nurse), coded and entered into the electronic file.
Confidentiality of data was ensured in accordance with
current applicable codes, declarations and other provi-
sions. The results are shown in tables, and for quantita-
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TABLE 1
DISTRIBUTION OF SUBJECTS ACCORDING TO THE VALUE OF
THEIR BMI
Body mass index (BMI) N Percentage (%)
<19 kg/m2 7 0.5
19–24.99 kg/m2 290 22.6
25–29.99 kg/m2 618 48.2
30 kg/m2 367 28.6
Total 1282 100.0
BMI – body mass index, kg – kilogram, m – meter
TABLE 2
DISTRIBUTION OF SUBJECTS ACCORDING TO SELECTED ANTHROPOMETRIC VARIABLES
Selected anthropometric
variables
N Mean SD Min.
Percentiles
Max.
25. 50. (Median) 75.
Weight (kg) 1283 83.38 13.97 16.00 75.00 83.00 92.00 161.00
Height (cm) 1283 172.31 9.20 104.00 166.00 173.00 178.00 198.00
BMI (kg/m2) 1282 28.10 4.41 4.58 25.27 27.59 30.48 68.42
Waist circumference (cm) 1221 100.38 14.38 33.00 93.00 100.00 109.00 195.00
Hip circumference (cm) 1209 102.38 12.49 37.00 96.00 102.00 110.00 151.00
WHR 1209 0.98 0.12 0.64 0.91 0.97 1.04 1.87
N – number, SD – standard deviation, Min. – minimum, Max. – maximum, kg – kilogram, cm – centimetre, BMI – body mass index,
WHR – waist to hip ratio
tive variables descriptive statistics were done with ap-
propriate measures of central tendency and variability
(mean, standard deviation, medians, associated inter-
quartile ranges). Normal distribution of quantitative va-
riables was tested by Kolmogorov-Smirnov test, and then
appropriate parametric (t-test for independent samples
and analysis of variance – ANOVA) or nonparametric
tests (Mann-Whitney U test, Kruskal-Wallis test) were
used. The c2-test was also used.
Statistically significant results were considered those
with p values <0.05. Statistical analysis was made using
the software PASW version 17.02 (Chicago Inc., IL, www.
spss.com).
Results
Table 1 shows the distribution of subjects according
to the value of their BMI. 48.2% of subjects were over-
weight, and 28.6% were obese, the data was not available
for 16 subjects. The data on the measured anthropo-
metric variables (weight, height, BMI, waist circumfer-
ence, hip circumference, WHR) is shown in Table 2. Com-
parison of selected anthropometric variables according
to sex is shown in Table 3. Only for BMI there were
no statistically significant differences according to sex.
Male subjects have statistically significantly larger body
weight (86.34±12.97 kg vs. 76.15±13.73 kg, p< 0.001)
and bigger height (175.86±7.37 cm vs. 163.64±7.30 cm,
p<0.001). Male subjects also have larger waist circum-
ference, hip circumference and WHR (waist circumfer-
ence: 101.46±14.11 cm vs. 97.72±14.71 cm, p<0.001; hip
circumference: 101.51±11.86 cm vs. 104.49±13.72 cm,
p=0.002; WHR: 1.00±0.11 vs. 0.94±0.12, p<0.001). For
all comparisons Mann-Whitney U test was used. Com-
parison of subjects according to their sex and BMI group
presented in Table 4 showed borderline statistical signifi-
cance in a way that males were more frequently over-
weight (49.8% vs. 44.4%, p=0.054, c2 test) and that fe-
males were more frequently obese (32.8% vs. 26.9%,
p=0.054, c2-test).
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TABLE 3
SELECTED ANTHROPOMETRIC VARIABLES ACCORDING TO SEX
Selected anthropometric
variables
Sex N Mean SD Min.
Percentiles
Max. p
25. 50. (Median) 75.
Weight (kg)
Male 911 86.34 12.97 16.00 78.00 85.00 95.00 161.00
<0.001
Female 372 76.15 13.73 48.00 65.13 75.00 84.00 142.00
Height (cm)
Male 911 175.86 7.37 104.00 171.00 176.00 180.00 198.00
<0.001
Female 372 163.64 7.30 145.00 160.00 163.50 168.00 188.00
BMI (kg/m2)
Male 910 27.95 4.22 4.58 25.25 27.47 30.20 68.42
0.171
Female 372 28.45 4.83 16.33 25.39 27.68 31.14 49.54
Waist circumference (cm)
Male 868 101.46 14.11 33.00 94.00 100.00 110.00 195.00
<0.001
Female 353 97.72 14.71 45.00 89.00 98.00 107.00 139.00
Hip circumference (cm)
Male 858 101.51 11.86 37.00 96.00 101.00 108.00 151.00
0.002
Female 351 104.49 13.72 57.00 96.00 103.00 112.00 145.00
WHR
Male 858 1.00 0.11 0.75 0.94 0.98 1.05 1.87
<0.001
Female 351 0.94 0.12 0.64 0.86 0.92 1.00 1.48
Mann-Whitney U test was used, p<0.05 is considered statistically significant
N – number, SD – standard deviation, Min. – minimum, Max. – maximum, kg – kilogram, cm – centimetre, BMI – body mass index,
WHR – waist to hip ratio
TABLE 4




<19 kg/m2 19–24.99 kg/m2 25–29.99 kg/m2 30 kg/m2
Male 3 (0.3%) 209 (23.0%) 453 (49.8%) 245 (26.9%) 910 (100.0%)
Female 4 (1.1%) 81 (21.8%) 165 (44.4%) 122 (32.8%) 372 (100.0%)
Total 7 (0.5%) 290 (22.6%) 618 (48.2%) 367 (28.6%) 1282 (100.0%)
c2=7.648; df=3; p=0.054
c2 test was used, p<0.05 is considered statistically significant
% – percent, df – degrees of freedom
Subjects were also divided into two groups according
to their WHR values – one with increased WHR (>1 for
males or >0.85 for females) and one with WHR values
within normal range (1 for males or 0.85 for females).
A total of 659 subjects (54.5%) were centrally obese – had
increased WHR, and 550 subjects (45.5%) had WHR
within normal range. Data on WHR were not available
for 89 subjects. Prevalence of central obesity in females
was almost double than in males (79.5% vs. 44.3%, p<
0.001, Table 5, c2-test).
Discussion
Our group presents in this article the available data
on the prevalence of overweight, obesity and central obe-
sity among Croatian hospitalized CHD patients. This
risk factor is one of interim risk factors for CVD and, al-
though modifiable, represents a more complex type of
cardiovascular risk than behavioural risk factors such as
smoking or physical inactivity23.
There is substantial evidence in currently available
literature which shows that presence of overweight and
obesity is strongly connected with numerous risk factors
for the development of CVD1,2 and cardiovascular mor-
tality3. Severe obesity has been shown to significantly re-
duce life expectancy for 5–20 years6. Some estimates say
that at the turn of the century over one billion people
were overweight, of which at least 300 million were
obese; this supports the broad consensus that today we
can truly speak of global epidemic of overweight and
obesity24. In this context, central obesity plays a critical
role, as it bears additional health risks, such as insulin
resistance25, increased risk for occurrence of cardiometa-
bolic diseases7 and increased incidence of cardiovascular
events8; as it increases mortality both from cardiovascu-
lar and malignant diseases9. Recently published data
suggest that obesity prevalence is increasing worldwide
in parallel with type 2 diabetes26.
It is no wonder that BMI is frequently used in clinical
practice, as it is frequently available from records from
everyday clinical practice, modifiable with lifestyle chan-
ges and it has been shown that its reduction has favour-
able effects on other cardiovascular risk factors27. Physi-
cians and other health professionals should be encour-
aged to always record patient weight and height.
When comparing the data from this study with other
recent and relevant studies that were also performed in
Croatian CHD patient population, comparisons are prin-
cipally only possible with only one other study which also
recorded data on the prevalence of overweight and obe-
sity – the study on European action on secondary preven-
tion by intervention to reduce events (EUROASPIRE
III)28 which was performed in 22 European countries in
2006, one of the countries that participated was also
Croatia.
As much as 48.2% of subjects in the surveyed popula-
tion were only overweight and 28.6% were obese (Table
1). There were some statistically significant differences
according to sex, men are bigger and heavier than wo-
men, they have larger both waist and hip circumference,
and WHR when compared to women (Table 3). When
compared to the available data from EUROASPIRE III,
where there were 35% of obese CHD patients in the
whole European sample and 39% in the Croatian sam-
ple28, one can see a modest decrease in the prevalence of
obesity in this population, which is good news and pro-
vides hope that at least some of the preventive measures
that have been undertaken seem to be effective in prac-
tice. While men seem to be statistically borderline signifi-
cantly more frequently overweight than women (49.8%
vs. 44.4%, p=0.054, c2 test), this observed statistically
borderline significant difference in prevalence of obesity
in women (32.8% vs. 26.9% in men, p=0.054, Table 4) in
our surveyed population was also observed in EURO-
ASPIRE III study, but in that study from 2006 this differ-
ence was fully statistically significant (45% in females vs.
32% in males)28,29. Interestingly enough, our findings
from the population of Croatian CHD patients seem to
mirror those from CAHS from year 2003, where the
prevalences of obesity were similar in men and women,
but overweight was more frequent in men and central
obesity was more frequent in women (over half of female
general population was centrally obese!)16.
Measurement of WHR as a measure of central obesity
has shown that as much as 54.5% of surveyed subjects
are centrally obese. Again, comparison with the data
from EUROASPIRE III (where central obesity was de-
fined only by measure of waist circumference) on the Eu-
ropean level there were 53% of centrally obese patients,
while at the same time in the Croatian sample there were
78.8% of CHD patients in this category28, so here, like in
the case of obesity as measured through BMI, it is not ex-
aggerated to say that findings from our study do give
some reassuring data, at least in the field of obesity.
However, one should bear in mind that persons with nor-
mal BMI, but increased waist circumference have 20%
higher risk of dying than persons with normal BMI and
waist circumference within normal range as recommen-
ded by the WHO (102 cm for men, 88 cm for women)11.
Presented data on prevalences of overweight, obesity
and central obesity show that although there are some
reassuring trends, there is still considerable amount of
work to be done if the prevalence of this cardiovascular
risk is to be further reduced factor among Croatian CHD
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TABLE 5




1 for M or
0.85 for F
>1 for M or
>0.85 for F
Male 478 (55.7%) 380 (44.3%) 858 (100.0%)
Female 72 (20.5%) 279 (79.5%) 351 (100.0%)
Total 550 (45.5%) 659 (54.5%) 1209 (100.0%)
c2=124.455; df=1; p<0.001; F – female; M – male
patients. While the prevalence of obesity seems to be on
the decline, the prevalence of overweight is rising, which
may be just an early warning sign of an incoming wave of
obesity epidemic in future years. It is only the next stud-
ies in this area in the following years that will confirm or
dispute this sign. In the meantime, it is imperative that
the work on prevention of overweight and obesity contin-
ues, so that, hopefully, this cardiovascular risk factor can
further be reduced.
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PREVALENCIJA PREKOMJERNE TJELESNE TE@INE I PRETILOSTI U HOSPITALIZIRANIH
KORONARNIH BOLESNIKA U HRVATSKOJ
S A @ E T A K
Cilj ovog rada bio je pokazati prevalenciju prekomjerne tjelesne te`ine i pretilosti uz izabrane antropometrijske
varijable na uzorku bolesnika hospitaliziranih zbog koronarne bolesti u Republici Hrvatskoj (N=1,298). Prevalencija
prekomjerne tjelesne te`ine i pretilosti u ispitivanoj populaciji bila je visoka: 48,2% ispitanika imalo je prekomjernu
tjelesnu te`inu i 28,6% bilo je pretilo (mjerenom putem indeksa tjelesne mase), dok je 54,5% ispitanika bilo centralno
pretilo (mjereno putem omjera struk-bokovi). Prikazani podaci o prevalencijama prekomjerne tjelesne te`ine, pretilosti
i centralne pretilosti pokazuju da, iako postoje neki ohrabruju}i trendovi, jo{ uvijek je potrebno dosta u~initi kako bi se
prevalencija ovog ~imbenika rizika za kardiovaskularnu bolest dodatno smanjila kod bolesnika s koronarnom bolesti u
Hrvatskoj. Dok se ~ini kako se prevalencija pretilosti smanjuje, raste prevalencija prekomjerne tjelesne te`ine, {to bi
mogao biti samo rani znak upozorenja nadolaze}eg vala epidemije pretilosti u idu}im godinama.
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